Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma - PubMed (original) (raw)
Review
Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma
Edgardo S Santos et al. Leuk Lymphoma. 2006 Dec.
Abstract
Monoclonal antibodies labeled with radionuclides have become an important therapeutic tool in the treatment of patients with non-Hodgkin's lymphomas (NHL). At the present time, their use in the US is approved for patients with rituximab-resistant, low-grade, follicular or transformed NHL. Encouraging responses seen in the relapsed and refractory patients have prompted their evaluation in earlier disease or in other histologic sub-types either alone or in combination with conventional chemotherapy. Additionally, they have been included as preparative regimens for stem cell transplant protocols within the context of clinical trials. This review discusses the latest clinical trials and future directions of radioimmunoconjugates in the treatment of NHL, with emphasis on US Food and Drug Administration (FDA) approved radioimmunoconjugates, namely 131I-tositumomab and 90Y-ibritumomab tiuxetan.
Similar articles
- Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Witzig TE, et al. J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial. - Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter JN, Nademanee A. Molina A, et al. Curr Stem Cell Res Ther. 2007 Sep;2(3):239-48. doi: 10.2174/157488807781696230. Curr Stem Cell Res Ther. 2007. PMID: 18220907 Review. - Yttrium 90 ibritumomab tiuxetan in lymphoma.
Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K; Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Cheung MC, et al. Leuk Lymphoma. 2006 Jun;47(6):967-77. doi: 10.1080/10428190600572582. Leuk Lymphoma. 2006. PMID: 16840185 Review. - Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Ansell SM, et al. J Clin Oncol. 2002 Sep 15;20(18):3885-90. doi: 10.1200/JCO.2002.10.143. J Clin Oncol. 2002. PMID: 12228209 - The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
Bischof Delaloye A. Bischof Delaloye A. Leuk Lymphoma. 2003;44 Suppl 4:S29-36. doi: 10.1080/10428140310001616935. Leuk Lymphoma. 2003. PMID: 15154740 Review.
Cited by
- Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Jensen MC, et al. Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56. doi: 10.1016/j.bbmt.2010.03.014. Epub 2010 Mar 19. Biol Blood Marrow Transplant. 2010. PMID: 20304086 Free PMC article. Clinical Trial.